Athens Medical Center S.A.
- Address
- lock Available on a paid plan
Cardiovascular Diseases and Kidney Health
At Athens Medical Center S.A., research in cardiovascular diseases focuses on conditions such as atherosclerotic cardiovascular disease, hypertension, and elevated Lp(a), with added attention to chronic kidney disease and overall heart-kidney risk. The trials are aimed at testing new therapies and assessing whether they can reduce major cardiovascular events, protect kidney function, and improve long-term outcomes.
- Studies in atherosclerotic cardiovascular disease and elevated Lp(a)
- Trials for hypertension linked to obesity and diabetes
- Research on chronic kidney disease and prevention of worsening kidney outcomes
These studies reflect a strong interest in treatments that may lower the risk of heart attacks, stroke, and related complications while supporting better chronic disease control.
Diabetes, Obesity, and Metabolic Disorders
The Department of Internal Medicine & Diabetes is actively involved in trials for type 2 diabetes, obesity, and overweight, often alongside related metabolic conditions. The research is centered on improving blood sugar control, supporting weight loss, and evaluating whether newer therapies can also reduce cardiovascular risk.
- Trials in type 2 diabetes focused on glucose control and treatment effectiveness
- Studies in obesity and overweight examining weight reduction and related health benefits
- Research connecting metabolic treatment with cardiovascular disease prevention
Several projects also look at broader metabolic health, including how treatment may affect long-term complications in people living with diabetes or excess body weight.
Oncology and Gastrointestinal Cancers
Clinical research at the site includes a substantial neoplasms portfolio, with studies in colorectal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, non-small cell lung cancer, and pancreatic cancer. These trials are mainly designed to evaluate new treatment combinations and compare their effectiveness against current standard approaches.
- Studies in colorectal cancer, including metastatic and biomarker-defined disease
- Trials for gastric and gastroesophageal junction cancers
- Research in non-small cell lung cancer and pancreatic ductal adenocarcinoma
This oncology work emphasizes improving survival, delaying disease progression, and identifying better options for patients with advanced or difficult-to-treat cancers.
Dermatology and Immune-Mediated Skin Disease
In skin and connective tissue diseases, the site is studying cutaneous lupus erythematosus and hidradenitis suppurativa. The purpose of these trials is to assess new treatment options that may reduce symptoms, improve skin manifestations, and offer better disease control for patients with chronic inflammatory conditions.
- Trials in cutaneous lupus erythematosus targeting skin improvement
- Studies in hidradenitis suppurativa focused on symptom relief and response rates
- Research on immune-driven skin disease with an emphasis on treatment effectiveness
These investigations support a growing interest in therapies for persistent dermatologic diseases that can strongly affect quality of life.
Cross-Disciplinary Metabolic and Cardiometabolic Research
The trial portfolio at Athens Medical Center S.A. also brings together nutritional and metabolic diseases with cardiovascular research, reflecting the close link between metabolism, heart health, and weight-related illness. The studies are intended to test whether emerging therapies can improve multiple health outcomes at once, including blood sugar, body weight, blood pressure, and cardiovascular risk.
- Integrated studies in type 2 diabetes and hypertension
- Research in overweight and obesity with attention to cardiometabolic benefit
- Trials evaluating whether new treatments can improve several related chronic conditions together
This broad research focus highlights the site’s role in studying diseases that often occur together and require coordinated long-term care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Novo Nordisk A/S2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Athens Medical Center S.A.
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Study of Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy | Amgen Inc. | Phase III | Not Recruiting | Apr 2025 | — |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 3 | Unknown | 2023-11-07 | 2023-11-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.